The present disclosure provides methods and systems for ghost cytometry (GC), which may be used to produce an image of an object without using a spatially resolving detector. This may be used to perform image-free ultrafast fluorescence “imaging” cytometry, based on, for example, a single pixel detector. Spatial information obtained from the motion of cells relative to a patterned optical structure may be compressively converted into signals that arrive sequentially at a single pixel detector. Combinatorial use of the temporal waveform with the intensity distribution of the random or pseudo-random pattern may permit computational reconstruction of cell morphology. Machine learning methods may be applied directly to the compressed waveforms without image reconstruction to enable efficient image-free morphology-based cytometry. Image-free GC may achieve accurate and high throughput cell classification as well as selective sorting based on cell morphology without a specific biomarker, which have been challenging using conventional flow cytometers.
A liquid crystal element is provided that can inhibit occurrence of voltage drop between one end and the other end of each electrode. A liquid crystal element (100) includes a liquid crystal layer LQ, a plurality of first arcuate electrodes (1), and a plurality of second arcuate electrodes (2). The first arcuate electrodes (1) are disposed concentrically about an optical axis (AX) of the liquid crystal element (100) and applies first voltage (Vi) to the liquid crystal layer (LQ). The second arcuate electrodes (2) are disposed concentrically about the optical axis (AX) and applies second voltage (V2) to the liquid crystal layer (LQ).
G02F 1/29 - Dispositifs ou dispositions pour la commande de l'intensité, de la couleur, de la phase, de la polarisation ou de la direction de la lumière arrivant d'une source lumineuse indépendante, p.ex. commutation, ouverture de porte ou modulation; Optique non linéaire pour la commande de la position ou de la direction des rayons lumineux, c. à d. déflexion
G02B 3/14 - Lentilles remplies d'un fluide ou à l'intérieur desquelles le vide a été fait à distance focale variable
3.
CALIBRATION DEVICE, RAMAN SPECTROSCOPY MEASUREMENT DEVICE, AND WAVE NUMBER CALIBRATION METHOD
A spectroscopy measurement device according to the present embodiment comprises: a lamp light source (160) for generating lamp light having a plurality of emission lines; a plurality of inorganic materials; an objective lens (50) on which the lamp light and Raman scattered light from the plurality of inorganic materials impinge; a spectrometer (60) that spectrally detects the lamp light and the Raman scattered light from the objective lens (50); and a processing unit (70) that calculates a calibration wavelength axis of the spectrometer (60) on the basis of the wavelengths of the plurality of emission lines, calculates the incident wavelength of the laser light on the basis of the Raman bands of the Raman scattered light on the calibration wavelength axis, and converts the calibration wavelength axis to a wavenumber axis using the incident wavelength.
The present invention accurately evaluates the effects, on organs at risk, of radiation from radiation sources. This radiation dose analysis method comprises a reference axis determination step (S1) for: acquiring a three-dimensional medical image, which is an image obtained by imaging a subject present where an applicator (50) capable of accommodating a radiation source is installed in the vicinity of an object to be irradiated with radiation emitted from the radiation source, said image showing the installed applicator; and determining a reference axis of the applicator (50) shown in the three-dimensional medical image. Said method also comprises a first radiation dose analysis step (S4) for analyzing, on the basis of a distance from the reference axis of each of a plurality of virtual cylindrical surfaces having different radii with the reference axis serving as the central axis, a radiation dose reaching each of the plurality of virtual cylindrical surfaces from the radiation source.
The present invention provides an image classification learning device that makes it possible to learn a "concept" to be used by a post-learning model to make a determination. A concept learner 200 performs machine learning of a plurality of concepts in image data on the basis of learning data including the image data and an image label. A concept prototype processing unit 2100 is an attention mechanism that, in a concept matrix comprising slot vectors, converts the slot vectors according to image features defined in the slot vectors, the slot vectors respectively corresponding to a plurality of concepts and defining an image region in which feature quantities emphasized in identification processing by an image identification means appear. A learning processing control unit 700 controls learning processing so as to decrease a loss calculated on the basis of: an identification loss that decreases as the identification rate of a classifier 400 increases, and a separation loss that decreases as the degree of mutual separation of the feature quantities corresponding to the plurality of concepts in a feature quantity space increases.
G06V 10/764 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant la classification, p.ex. des objets vidéo
G06V 10/77 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant l’intégration et la réduction de données, p.ex. analyse en composantes principales [PCA] ou analyse en composantes indépendantes [ ICA] ou cartes auto-organisatrices [SOM]; Séparation aveugle de source
G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux
6.
DEVICE, IONIC CURRENT MEASUREMENT APPARATUS, ZETA POTENTIAL MEASUREMENT APPARATUS, IONIC CURRENT MEASUREMENT METHOD, AND ZETA POTENTIAL MEASUREMENT METHOD
An object is to provide a device that can measure a moving time (velocity) of a single particle with high accuracy, and an ion current measuring apparatus and a zeta potential measuring apparatus with the device, and an ion current measuring method and a zeta potential measuring method. The object can be achieved by a device used for measurement of ion current, the device including: a substrate; and a channel formed in the substrate. The channel includes a sample liquid supply channel, a sample collection channel, and constricted channel formed between the sample liquid supply channel and the sample collection channel. The constricted channel includes three or more constricted parts each formed with a protrusion part, the three or more constricted parts are formed substantially straight in a direction from the sample liquid supply channel to the sample collection channel, and when the width of each of the constricted parts is defined as 1, the spacing between adjacent constricted parts is 0.5 to 3.
[Problem] To directly bond a metal layer in the shape of a thin line to a surface of a ceramic substrate. [Solution] A method for producing a ceramic/metal bonded object which comprises: causing laser beams to strike on a surface of a ceramic substrate while sweeping the laser beams; simultaneously therewith, feeding a solid metallic material toward a region (hereinafter, referred to as "irradiated area") in the ceramic-substrate surface, the region being irradiated with the laser beams, so that the metallic material being supplied is also in the state of being irradiated with the laser beams, thereby melting the metallic material while heating the ceramic-substrate surface located in the irradiated area; and causing the molten metallic material to adhere to the ceramic-substrate surface and then solidifying the metallic material.
C23C 24/10 - Revêtement à partir de poudres inorganiques en utilisant la chaleur ou une pression et la chaleur avec formation d'une phase liquide intermédiaire dans la couche
C23C 26/00 - Revêtements non prévus par les groupes
C23C 26/02 - Revêtements non prévus par les groupes par application au substrat de matériaux fondus
8.
EVALUATION DEVICE, EVALUATION SYSTEM, EVALUATION METHOD, EVALUATION PROGRAM, AND RECORDING MEDIUM
The present invention relates to an evaluation device 4 for evaluating the severity of pneumonia in a target patient, comprising: an acquisition unit 42 for acquiring a respiratory waveform of the target patient; a calculation unit 43 for calculating a value of an index indicating instability of a respiratory cycle or a respiratory frequency from the respiratory waveform; and an evaluation unit 44 for evaluating the severity based on the calculated value.
INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (France)
ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP) (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
ICM (INSTITUT DU CERVEAU ET DE LA MOELLE EPINIÈRE) (France)
SORBONNE UNIVERSITÉ (France)
OSAKA UNIVERSITY (Japon)
Inventeur(s)
Cartier-Lacave, Nathalie
Besnard-Guerin, Corinne
Rousselot, Lisa
Mochizuki, Hideki
Tada, Satoru
Abrégé
The present invention relates to the treatment alpha-synucleinopathies. In this study, the inventors showed that restoring brain cholesterol pathway and defective autophagy by AAV- CYP46A1 delivery, as evidenced in several neurodegenerative pathologies, could be a relevant therapeutic approach in alpha-synucleinopathies and particularly in PD. Thus the present invention relates to a vector for use in the treatment of alpha-synucleinopathies, which vector comprises the full sequence of cholesterol 24-hydroxylase encoding nucleic acid.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
National Institutes of Biomedical Innovation, Health and Nutrition (Japon)
Kagami Inc. (Japon)
Inventeur(s)
Isaka, Yoshitaka
Kimura, Tomonori
Kimura, Shihoko
Mita, Masashi
Abrégé
Provided herein is a method for providing information about virus infection and/or virus infection disease in a subject, comprising: making a determination on the detection and/or stage classification of virus infection and/or virus infection disease in the subject using an indicator associated with a D-amino acid in the subject; and providing information about virus infection and/or virus infection disease in the subject based on the results of the determination.
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p.ex. basé sur des systèmes experts médicaux
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
G16H 20/10 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p.ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médicaments ou des médications, p.ex. pour s’assurer de l’administration correcte aux patients
11.
BORONIC ACID COMPOUND AND METHOD FOR PRODUCING SAME
The invention provides a method for producing radiolabeled tyrosine derivatives with good purity and stability, by a safe method suitable for industrial production of pharmaceuticals. The invention relates to a method for producing Compound (5) and Radiolabeled Compound (6) as follows:
The invention provides a method for producing radiolabeled tyrosine derivatives with good purity and stability, by a safe method suitable for industrial production of pharmaceuticals. The invention relates to a method for producing Compound (5) and Radiolabeled Compound (6) as follows:
The invention provides a method for producing radiolabeled tyrosine derivatives with good purity and stability, by a safe method suitable for industrial production of pharmaceuticals. The invention relates to a method for producing Compound (5) and Radiolabeled Compound (6) as follows:
wherein each symbol is as defined in the description.
C07B 59/00 - Introduction d'isotopes d'éléments dans les composés organiques
C07C 227/16 - Préparation de composés contenant des groupes amino et carboxyle liés au même squelette carboné à partir de composés contenant déjà des groupes amino et carboxyle ou leurs dérivés par des réactions n'impliquant pas les groupes amino ou carboxyle
C07F 13/00 - Composés contenant des éléments des groupes 7 ou 17 de la classification périodique
12.
METHOD FOR PRODUCING DNA-EDITED EUKARYOTIC CELL, AND KIT USED IN THE SAME
C12N 15/90 - Introduction stable d'ADN étranger dans le chromosome
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
In the present invention, each of a plurality of pieces of training data used for creating a learned model for estimating a plan of a subject includes information on brain waves and is used for machine learning on the basis of at least some of a plurality of parameters. The program causes a computer to execute a step for creating a plurality of learned models by performing machine learning on each of a plurality of sets of a plurality of parameters, a step for calculating sensitivity and specificity with respect to each of the plurality of learned models, and a step for displaying a plurality of mosaic graphs on the same screen. Each of the plurality of mosaic graphs indicates information on the sensitivity in at least some of the plurality of sets. Assumed specificities with respect to the plurality of mosaic graphs are different from one another.
A glass powder composite comprising: a first glass powder which contains a first glass containing at least one type of element and from which the first glass elutes in a first period; and a second glass powder which contains a second glass containing at least one element different from the element of the first glass, and from which the second glass elutes in a second period different from the first period.
C12N 15/90 - Introduction stable d'ADN étranger dans le chromosome
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (Japon)
Inventeur(s)
Tsutsui Makusu
Kawai Tomoji
Yokota Kazumichi
Abrégé
Provided are an ionic current measurement method and an ionic current measurement device capable of increasing an S/N ratio of a measurement result of a change in an ionic current. The ionic current measurement device comprises a board having a first surface and a second surface, a through-hole that penetrates through from the first surface toward the second surface to allow a charged sample to pass through, a first chamber member which, together with a surface of the first surface including a first opening of the through hole forms a first chamber that is filled with a first electrolytic solution, and a second chamber member which, together with a surface of the second surface including a second opening of the through hole forms a second chamber that is filled with a second electrolytic solution, and the ionic current measurement method includes a step for applying a voltage across the first electrolytic solution and the second electrolytic solution to cause the charged sample contained in one of the chambers to pass through the through-hole in a direction toward the other chamber, and a step for measuring a change in an ionic current when the charged sample passes through the through-hole. Furthermore, the first electrolytic solution and the second electrolytic solution have different dielectric constants.
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
17.
METHOD FOR PRODUCING THREE-DIMENSIONAL TISSUE BODY AND METHOD FOR PROMOTING DIFFERENTIATION OF ADIPOSE-DERIVED STEM CELLS
Kyoto Prefectural Public University Corporation (Japon)
Inventeur(s)
Kitano, Shiro
Matsusaki, Michiya
Louis, Fiona
Sowa, Yoshihiro
Abrégé
A method for producing a three-dimensional tissue construct comprising mature adipocytes, comprising incubating cells comprising at least fat-derived stein cells in the presence of one or more fatty acids selected from the group consisting of erucic acid, elaidic acid, oleic acid, palmitoleic acid, myristoleic acid, phytanic acid, and pristanic acid.
A permanent magnet-type rotary electric machine includes a stator, a first rotor, and a second rotor. The stator includes a stator core, a plurality of stator teeth, a plurality of stator slots, a plurality of stator magnets, and a stator coil. The first rotor is disposed inside the stator core relative to the plurality of stator magnets. The second rotor is disposed inside the stator core relative to a plurality of first pole pieces. The second rotor includes a plurality of second pole pieces. A proportion of the number of the plurality of stator slots to the number of poles of the plurality of second pole pieces of the second rotor is greater than 1.25 and less than 1.5, or greater than 1.5 and less than 3.0.
The present invention addresses the problem of providing a cMLCK activator which can enhance myocardial contraction without the need to increase the concentration of calcium in cells. The problem is solved by a cMLCK activator comprising a 8-hydroxyquinoline compound represented by general formula (I) (wherein R1represents a hydrogen atom or the like; R2represents R7CO- (wherein R71-61-6 alkyl group or the like) or the like; R3represents a hydrogen atom or the like; and R4, R5and R6 each independently represent a hydrogen atom or the like) or a pharmaceutically acceptable salt thereof, or a solvate of the compound or the pharmaceutically acceptable salt.
C07D 215/28 - Alcools; Leurs éthers avec les atomes d'halogènes ou les radicaux nitro en positions 5, 6 ou 7
C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 401/10 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles aromatiques
C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
C07D 405/06 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
C07D 405/12 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
C07D 417/10 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles aromatiques
C07D 417/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 455/04 - Composés hétérocycliques contenant des systèmes cycliques quinolizine, p.ex. alcaloïdes de l'émétine, protoberbérine; Dérivés alkylènedioxy des dibenzo [a, g] quinolizines, p.ex. berbérine contenant des systèmes cycliques quinolizine directement condensés avec au moins un carbocycle à six chaînons, p.ex. protoberbérine; Dérivés alkylènedioxy des dibenzo [a, g] quinolizines, p.ex. berbérine contenant un système cyclique quinolizine condensé avec un seul carbocycle à six chaînons, p.ex. julolidine
A spectrometry apparatus (1) according to an embodiment includes a detection object lens that signal light from a sample S enters, a slit (41) through which the signal light passes, a wavelength dispersive element that disperses the signal light having passed the slit (41) in accordance with a wavelength, an optical detector (50) that detects the signal light that has been subjected to wavelength dispersion in the wavelength dispersive element, scanning means for scanning a detection region of the optical detector (50) in the sample, a processing unit (51) that generates a spectral image, based on a detection signal of the optical detector (50), and an illumination optical system (10) that illuminates the sample from a side of the detection object lens.
The present disclosure provides a pharmaceutical composition for treating or preventing T cell-related disorders, the pharmaceutical composition containing induced regulatory T cells having high functionality and a stable immunosuppression action. Also provided are induced regulatory T cells containing a chimeric antigen receptor (CAR). The present disclosure provides the pharmaceutical composition for treating or preventing T cell-related disorders, the composition containing, as an active ingredient, induced regulatory T cells having at least one characteristic selected from the group consisting of CTLA4 positivity, NT5E positivity, ITGAE (CD103) positivity, and AREG positivity. The present disclosure provides induced regulatory T cells containing a chimeric antigen receptor (CAR).
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p.ex. cellules transformées par des virus
A61K 35/17 - Lymphocytes; Lymphocytes B; Lymphocytes T; Cellules tueuses naturelles; Lymphocytes activés par un interféron ou une cytokine
A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p.ex. antiacides, antisécrétoires, protecteurs de la muqueuse
A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p.ex. antidiabétiques
A61P 5/14 - Médicaments pour le traitement des troubles du système endocrinien des hormones thyroïdiennes, p.ex. T3, T4
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
Provided are an exceptional agent and method for inducing differentiation from dental pulp cells into odontoblasts. Also provided are an exceptional pharmaceutical composition and pulp capping agent for dentin regeneration. This agent for inducing differentiation from dental pulp cells into odontoblasts contains an ammonium salt and at least one selected from the group consisting of halous acids, halous acid ions, and halites. Furthermore, the pharmaceutical composition and/or pulp capping agent for dentin regeneration has the aforementioned differentiation-inducing agent as an active ingredient. More specifically, the differentiation-inducing agent induces differentiation from dental pulp cells into odontoblasts by causing desulfation of the sulfate groups of heparan sulfate proteoglycans on the dental pulp cell surface.
Provided are: an orthogonal modulation device that is capable of measuring, with excellent precision, the spuriousness of modulated waves without limiting the performance of a circuit configuration; a method for measuring spuriousness; and a method for correcting orthogonal modulation. This orthogonal modulation device 12 has a modulation unit 17 and a measurement unit 18, the modulation unit 17 having a first orthogonal modulation unit 21 that outputs an orthogonally modulated TX1 signal, and a second orthogonal modulation unit 22 that outputs an orthogonally modulated TX2 signal. The TX1 signal and the TX2 signal include desired waves having the same frequency as each other. When local leaks and image components of the TX1 signal and the TX2 signal are measured by the measurement unit 18, the desired waves of the TX1 signal and the desired waves of the TX2 signal are adjusted so as to be inverted at the same amplitude as each other, and the local leaks and image components are measured from synthesized waves of the TX1 signal and the TX2 signal.
NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY (Japon)
OSAKA UNIVERSITY (Japon)
Inventeur(s)
Yokota Takanori
Yoshioka Kotaro
Kuroda Takayuki
Obika Satoshi
Yamaguchi Takao
Abrégé
The present invention addresses the problem of providing a novel nucleic acid molecule capable of simultaneously achieving both a high gene regulatory effect and toxicity reduction. Provided is a nucleic acid molecule that contains a base sequence that is complementary to at least a portion of a target gene or a transcription product thereof and that has an antisense effect on the target gene or a transcription product thereof, the nucleic acid molecule: containing [1] a center region containing at least three continuous deoxyribonucleosides, [2] a 5' wing region that is disposed on a 5'-end side of the center region and that contains a nonnatural nucleoside, and [3] a 3' wing region that is disposed on a 3'-end side of the center region and that contains a nonnatural nucleoside; and containing a 5'-modified nucleoside represented by formula (I) at the first, third, and/or ninth base positions from the 5' side of the center region.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
A61K 31/712 - Acides nucléiques ou oligonucléotides ayant des sucres modifiés, c. à d. autres que le ribose ou le 2'-désoxyribose
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Fujita, Katsumasa
Nishida, Kentaro
Sato, Hikaru
Tanaka, Hideo
Harada, Yoshinori
Abrégé
A diagnostic optical microscope according to the present embodiment includes at least one laser light source (11) configured to generate laser light for illuminating a sample (40) containing a light absorbing material, a lens configured to focus the laser light to be focused on the sample (40), scanning means for changing a focusing position of the laser light on the sample (40), and a light detector (31) configured to detect laser light transmitted through the sample (40) as signal light. A laser light intensity is changed to obtain a nonlinear region in which the laser light intensity and a signal light intensity have a nonlinear relation due to occurrence of saturation of absorption in the light absorbing material when the laser light intensity is maximized. An image is generated based on a nonlinear component of the signal light based on the saturation of absorption in the light absorbing material.
G01N 21/31 - Couleur; Propriétés spectrales, c. à d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p.ex. spectrométrie d'absorption atomique
G01N 33/483 - Analyse physique de matériau biologique
The prevent invention provides a radiolabeled tyrosine derivative which has excellent LAT1 selectability, higher retention at a tumor or cancer site, and a degree of clearance that does not cause side effects, and which can be safely manufactured at favorable purity by a safe method suitable for industrial production. The present invention provides a radiolabeled compound represented by formula (I), or a pharmaceutically-acceptable salt thereof. [In the formula, each symbol is as defined in the description.]
C07C 229/34 - Composés contenant des groupes amino et carboxyle liés au même squelette carboné ayant des groupes amino et carboxyle liés à des atomes de carbone acycliques du même squelette carboné le squelette carboné contenant des cycles aromatiques à six chaînons
A61K 41/00 - Préparations médicinales obtenues par traitement de substances par énergie ondulatoire ou par rayonnement corpusculaire
KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Niioka, Hirohiko
Sato, Junya
Takamatsu, Tetsuro
Matsumoto, Tatsuya
Nakao, Ryuta
Tanaka, Hiroyuki
Maebara, Syoji
Fukai, Shigeyuki
Abrégé
The present invention achieves an image translation device, for example, that can effectively utilize an existing diagnostic imaging model. An image translation device (1) comprises an image translation unit (22) that includes a first generator (221) and a second generator (222), the image translation unit (22) having learned the relationship between a color-related feature of a first image group obtained by capturing images of a tissue on which a first process including an embedding process and slicing has been performed, and a color-related feature of a second image group obtained by capturing images of the tissue on which a second process that does not include the embedding process and slicing has been performed. A first object image belonging to the first image group or a second object image belonging to the second image group is input to the image translation unit (22), which then outputs a first translation image generated from the first object image or a second translation image generated from the second object image.
C12M 1/34 - Mesure ou test par des moyens de mesure ou de détection des conditions du milieu, p.ex. par des compteurs de colonies
C12Q 1/00 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions
G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux
28.
CHEMICAL REACTION METHOD, REACTION VESSEL, AND REACTION DEVICE
Provided are a method for efficiently carrying out a chemical reaction, and a reaction vessel. The method comprises inserting, into a reaction vessel, a mixed solution containing a polar solute and a non-polar solute, separating the mixed solution in the reaction vessel into a first solution layer containing primarily the polar solute and a second solution layer containing primarily the non-polar solute, allowing light outside the reaction vessel to transmit primarily through the layer with lower light absorption among the first solution layer and the second solution layer, irradiating the light thereof toward the interface between the first solution layer and the second solution layer, and chemically reacting the polar solute and the non-polar solute. The reaction vessel is for the insertion of a mixed solution of a polar solute and a non-polar solute, and is provided with a light-guiding unit that is arranged such that light outside the reaction vessel is incident inside the reaction vessel and is transmitted primarily through the layer with lower light absorption among the first solution layer containing primarily the polar solute and the second solution layer containing primarily the non-polar solute, and the light is irradiated towards the interface between the first solution layer and the second solution layer.
C07C 51/29 - Préparation d'acides carboxyliques, de leurs sels, halogénures ou anhydrides par oxydation avec des composés contenant des atomes d'halogène, ceux-ci pouvant être formés in situ
B01J 19/12 - Procédés utilisant l'application directe de l'énergie ondulatoire ou électrique, ou un rayonnement particulaire; Appareils à cet usage utilisant des radiations électromagnétiques
B01J 19/18 - Réacteurs fixes avec éléments internes mobiles
B01F 23/43 - Mélange, p.ex. dispersion ou émulsion, selon les phases à mélanger Émulsion en utilisant des agitateurs entraînés
B01F 27/808 - Mélangeurs à agitateurs tournant dans des récipients fixes; Pétrins avec des agitateurs tournant autour d'un axe sensiblement vertical avec des agitateurs entraînés par le fond du récipient
B01F 33/40 - Mélangeurs utilisant l'agitation de gaz ou de liquide, p.ex. avec des tubes d'alimentation en air
B01F 33/45 - Mélangeurs magnétiques; Mélangeurs avec agitateurs à entraînement magnétique
B01F 33/452 - Mélangeurs magnétiques; Mélangeurs avec agitateurs à entraînement magnétique en utilisant des éléments d'agitation flottants indépendants
29.
POLYMER, RESIST COMPOSITION CONTAINING SAID POLYMER, METHOD FOR MANUFACTURING MEMBER USING SAME, AND PATTERN FORMATION METHOD
Provided are: a polymer which mitigates sensitivity decrease caused by a decrease in energy application density in patterning performed by irradiation with strong particle beams or electromagnetic waves of particles and photon energy and which is used in a resist composition having excellent development contrast characteristics and etching resistance; a resist composition containing said polymer; a method for manufacturing a member using said resist composition; and a pattern formation method. The polymer includes: a unit A which has an onium salt structure and generates acid by irradiation with particle beams or electromagnetic waves; and an organometallic compound-containing unit B having a metal atom selected from the group consisting of Sn, Sb, Ge, Bi, and Te, wherein the unit A is a polymer represented by formula (1). (In general formula (1), R1is one selected from the group consisting of a hydrogen atom, a linear, branched, or cyclic C1–C6 alkyl group, and a linear, branched, or cyclic C2–C6 alkenyl group, and at least one hydrogen atom in the alkyl group and alkenyl group in R1may be substituted with a substituent; L is one selected from the group consisting of a direct bond, a carbonyl oxy group, a carbonyl amino group, a phenylene diyl group, a naphthalene diyl group, a phenylene diyl oxy group, a naphthalene diyl oxy group, a phenylene diyl carbonyl oxy group, a naphthalene diyl carbonyl oxy group, a phenylene diyl oxy carbonyl group, and a naphthalene diyl oxy carbonyl group; Sp is one among a direct bond, a linear, branched, or cyclic C1–C6 alkylene group which may have a substituent, and a linear, branched, or cyclic C2–C6 alkenylene group which may have a substituent, and at least one methylene group in Sp may be substituted with a divalent heteroatom-containing group; M+is a sulfonium cation group or an iodonium cation group; X-is a monovalent anion group; f is an integer of 2-4, and f X-bonded to R, f M+corresponding to X-, f R1, f L, and f Sp may be respectively the same as or different from each other; and R is a C1-C6 f-valent hydrocarbon group which may have a substituent, at least one hydrogen atom in R may be substituted with a substituent, and at least one methylene group in R may be substituted with a divalent heteroatom-containing group.)
C08F 8/00 - Modification chimique par post-traitement
C08F 212/14 - Monomères contenant un seul radical aliphatique non saturé contenant un cycle substitué par des hétéro-atomes ou des groupes contenant des hétéro-atomes
Provided is an intervertebral disc therapeutic agent having favorable post-transplant engraftment. This intervertebral disc therapeutic agent contains scaffold-free artificial tissue in which synovium-derived mesenchymal stem cells form a three-dimensional structure.
Provided is a magnetic strain wave gear device that makes it possible to achieve both improvement of the efficiency of assembly work and suppression of decrease in energy conversion efficiency. A magnetic strain wave gear device includes: a stator having a stator core, a stator winding, and a stator magnet; a first rotor; and a second rotor. The second rotor includes a second rotor core provided with a plurality of rotor magnet insertion holes and a plurality of rotor magnets inserted into the plurality of respective rotor magnet insertion holes. The first rotor includes a cylindrical first rotor core and a first rotor end plate. The first rotor end plate has a rotor magnet passage hole through which the rotor magnets can be inserted into the rotor insertion holes from outside in a direction of a rotation shaft.
A wall thickness estimation method includes: obtaining behavioral information based on a video in which an organ wall or a blood vessel wall is captured using four-dimensional angiography, the behavioral information being numerical information about changes over time in a position of each of a plurality of predetermined points in the organ wall or the blood vessel wall; generating, based on the behavioral information obtained in the obtaining, estimation information that visualizes a strain of each of the plurality of predetermined points for estimating a thickness of the organ wall or a thickness of the blood vessel wall; and outputting the estimation information generated in the generating.
An information processing apparatus determines a combination of a first data qubit and a second data qubit that further reduces the energy represented by an energy equation. The energy equation includes first to third energy terms. The first energy term is used to identify the first data qubit on which a Z error has occurred. The second energy term is used to identify the second data qubit on which an X error has occurred. The third energy term reduces the energy as the number of data qubits each being a third data qubit on which both a Z error and an X error have simultaneously occurred increases. The information processing apparatus determines that a Y error has occurred on the third data qubit.
The present invention provides clinically applicable, safe and convenient, pharmaceutical compositions and methods for disease site-specific treatment. The pharmaceutical composition for disease site-specific treatment methods comprises a stealth liposome having a prostaglandin I2 receptor agonist encapsulated therein.
An exercise support apparatus includes an information processing unit that supports a setting of a next exercise menu for improvement to a targeted body, based on prior body motion information on a subject detected by a motion sensor. The information processing unit includes an image display processing unit that outputs distribution information on an amount of activity and a number of steps of at least one category obtained by classifying activity intensity that has been obtained from a target people group in advance, for each of the selected category, stored in a storage unit, and selected in advance, to a display unit, an activity amount processing unit that calculates the amount of activity and the number of steps for a same category as a selected category, based on body motion information on the subject, and that stores a calculation result in a measurement data storage unit, and an image display processing unit that outputs the amount of activity and the number of steps that have been calculated by the activity amount processing unit, to the display unit.
NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITION (Japon)
Inventeur(s)
Mizuguchi, Hiroyuki
Kawai, Kanae
Inui, Tatsuya
Abrégé
Research on methods for selective differentiation induction from pluripotent stem cells to small intestine epithelium-like cells is underway. The present invention provides an excellent highly functional small intestine epithelium-like cell population that can be used stably in tests for multidrug metabolism and permeability, and also provides a highly efficient method for producing cells. The present invention involves a method for inducing differentiation from pluripotent stem cells to small intestine epithelium-like cells, the method including following steps 1) and 2). 1) A step of inducing differentiation of pluripotent stem cells into entodermal cells. 2) A step of culturing the entodermal cells in a system comprising CHIR99021 and then inducing differentiation into small intestine epithelium-like cells. A small intestine epithelium-like cell population can be more efficiently obtained by seeding the small intestine epithelium-like cells produced by the differentiation induction method on a base material for producing an organoid or on a base material for two-dimensional culture and culturing.
C12N 5/071 - Cellules ou tissus de vertébrés, p.ex. cellules humaines ou tissus humains
C12N 1/00 - Micro-organismes, p.ex. protozoaires; Compositions les contenant; Procédés de culture ou de conservation de micro-organismes, ou de compositions les contenant; Procédés de préparation ou d'isolement d'une composition contenant un micro-organisme; Leurs milieux de culture
37.
CURED PRODUCT, SELF-HEALING MEMBER, ADHESIVE, CURED PRODUCT PRODUCTION METHOD, REPAIR METHOD, CURED PRODUCT DECOMPOSITION METHOD, AND MONOMER
Provided is a cured product obtained by curing a composition containing: a monomer A having an ethylenically unsaturated group and a host group in a molecule thereof, wherein the host group is a monovalent group obtained by removing one hydrogen atom or hydroxy group from cyclodextrin or a cyclodextrin derivative; a monomer B having a dynamic covalent bond in a molecule thereof; and a monomer C that may have the abovementioned dynamic covalent bond. In the cured product, at least one monomer selected from the group consisting of the monomer B and the monomer C can penetrate through the host group in a skewered manner, the monomer B and the monomer C each have, in a molecule thereof, at least two curable groups, which could react with the other type of curable group, and at least one set of the curable groups in the monomer B are coupled via the dynamic covalent bond. Thus, said cured product could exhibit excellent toughness and/or excellent strength.
C08G 59/40 - Macromolécules obtenues par polymérisation à partir de composés contenant plusieurs groupes époxyde par molécule en utilisant des agents de durcissement ou des catalyseurs qui réagissent avec les groupes époxyde caractérisées par les agents de durcissement utilisés
C09J 133/00 - Adhésifs à base d'homopolymères ou de copolymères de composés possédant un ou plusieurs radicaux aliphatiques non saturés, chacun ne contenant qu'une seule liaison double carbone-carbone et l'un au moins étant terminé par un seul radical carboxyle, o; Adhésifs à base de dérivés de tels polymères
38.
BONDED SHAPED BODY, AND METHOD FOR MANUFACTURING SAME
A bonded shaped body (1) comprises a disk portion (10) and a first blade portion (20) that is linear friction bonded to the disk portion (10). A structural body having the same shape as the bonded shaped body (1) and formed integrally by being carved from one solid block (100) of the same type of material as the first blade portion (20) serves as a comparison structural body (101). The first blade portion (20) has a homogeneous material structure exhibiting a longer cold-dwell fatigue life than that of the comparison structural body (101).
B23K 20/12 - Soudage non électrique par percussion ou par une autre forme de pression, avec ou sans chauffage, p.ex. revêtement ou placage la chaleur étant produite par friction; Soudage par friction
39.
MOLECULAR MEMORY, METHOD FOR MANUFACTURING MOLECULAR MEMORY, METHOD FOR DECODING MOLECULAR MEMORY, AND DEVICE FOR DECODING MOLECULAR MEMORY
The present invention addresses the problem of providing a molecular memory suitable for reading in a unit of a single molecule, a method for manufacturing the molecular memory, a method for decoding the molecular memory, and a device for decoding the molecular memory. Said problem is solved by a molecular memory comprising: an address region; and a memory region linked to the address region. The address region and the memory region are formed of molecules that generate tunnel current. The memory region is formed of four or more types of molecules selected from a first molecule group. The address region is composed of four or more types of molecules selected from a second molecule group. The molecules included in the first molecule group are either of types totally different from the types of molecules included in the second molecule group, or include both types that are the same and different with respect to the types of molecules included in the second molecule group. As a result, the molecules forming the address region and the molecules forming the memory regions are partially of different types.
[Problem] The present invention addresses the problem of providing an end effector, etc., with which it is possible to resolve the problem of finger jamming, in which an operation part collides with a surface on which an object is placed and becomes uncontrollable. [Solution] One embodiment of the present invention provides an end effector. The end effector comprises an operation part, a support body, and a detection surface. The operation part is configured to project toward one end, thereby coming into contact with an object. The support body is configured to flexibly support the operation part so that the position and/or orientation of the operation part is displaced when force generated due to contact between the operation part and the object is received. The detection surface is located at the other end of the operation part relative to the one end, the detection surface being configured to not come into contact with the object, and the position and/or orientation of the detection surface being displaced together with that of the operation part. In a state in which the end effector is attached to a robot arm, the detection surface is disposed so as to face a sensor that is capable of measuring the position and/or orientation of the detection surface.
B25J 15/08 - Têtes de préhension avec des éléments en forme de doigts
G01L 5/16 - Appareils ou procédés pour la mesure des forces, du travail, de la puissance mécanique ou du couple, spécialement adaptés à des fins spécifiques pour la mesure de plusieurs composantes de la force
41.
HEAT CONDUCTIVE JOINING STRUCTURE, HEAT CONDUCTIVE JOINING METHOD, HEAT SINK HAVING SAID HEAT CONDUCTIVE JOINING STRUCTURE, AND SEMICONDUCTOR DEVICE HAVING SAID HEAT CONDUCTIVE JOINING STRUCTURE
[Problem] To provide a heat conductive joining technology which is suitable for a joining structure of a semiconductor device, is capable of mitigating stress due to thermal deformation and preventing damage and peeling of a joining part, ensures low thermal resistance, and is capable of enhancing heat dissipation through heat transfer between members, and With which it is possible to maintain durability as a device without maintaining stiffness between the members in the stacking direction thereof, and maintain parallelism between the members during joining and assembly to enhance assembly accuracy. [Solution] This structure, which is composed of a joining layer 10 which is in close contact with a member 9 and performs heat transfer between the structure and the member 9, comprises: a metal-made porous base plate 11 having a plurality of through-holes 111 which extend in the thickness direction of the plate and are open in the front and rear plate surfaces of the plate; and a solder solidified body 12 composed of a filling part 121 filled in the though-holes 111 of the porous base plate 11, and solder films 122, 123 which are continuous to the filling part and expand on at least one plate surface, wherein the structure is brought into close contact with and joined to the facing member 9 by means of the solder film 122.
Provided are: a combination of a DNA construct comprising a first site-specific recombinase gene disposed so as to be capable of acting on a promoter of a first gene specific to a specified cell through a DNA construct comprising an n-th site-specific recombinase gene disposed so as to be capable of acting on a promoter of an n-th gene specific to said cell and a DNA construct comprising a killing gene disposed so as to be capable of acting on a constitutive promoter and in which each of transcriptional termination sequences disposed between sequences recognized and excised by the first through n-th site-specific recombinases is disposed between the constitutive promoter and the killing gene; a cell into which said combination has been introduced; and a non-human organism comprising said cell.
A61K 35/12 - Substances provenant de mammifères; Compositions comprenant des tissus ou des cellules non spécifiés; Compositions comprenant des cellules souches non embryonnaires; Cellules génétiquement modifiées
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
C12N 1/15 - Champignons; Leurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 1/19 - Levures; Leurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 1/21 - Bactéries; Leurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p.ex. cellules transformées par des virus
C12N 15/52 - Gènes codant pour des enzymes ou des proenzymes
43.
HEART FAILURE TREATMENT VIA CARDIOTONIC EFFECT BY TRPC3/6/7 CHANNEL ACTIVATION
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
INTER-UNIVERSITY RESEARCH INSTITUTE CORPORATION NATIONAL INSTITUTES OF NATURAL SCIENCES (Japon)
OSAKA UNIVERSITY (Japon)
KYOTO UNIVERSITY (Japon)
SHINSHU UNIVERSITY (Japon)
Inventeur(s)
Nishida, Motohiro
Nishiyama, Kazuhiro
Kato, Yuri
Nishimura, Akiyuki
Nagata, Ryu
Mori, Yasuo
Nakagawa, Yasuaki
Kuwahara, Koichiro
Abrégé
Provided is a drug for preventing or treating heart failure, that is effective and that does not have a blood pressure lowering effect. The present invention pertains to: a pharmaceutical composition for preventing or treating heart failure or skeletal muscle failure, the pharmaceutical composition containing a TRPC3/6/7 channel activator; and a related screening method.
A61K 31/454 - Pipéridines non condensées, p.ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p.ex. pimozide, dompéridone
A61K 31/495 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec deux azote comme seuls hétéro-atomes d'un cycle, p.ex. pipérazine
A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p.ex. rifampine, thiothixène
A61P 9/04 - Agents inotropes, c. à d. stimulants de la contraction cardiaque; Médicaments pour le traitement de l'insuffisance cardiaque
A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire
C07D 401/00 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
44.
METHOD FOR MANUFACTURING THREE-DIMENSIONAL SHAPED ARTICLE AND INSET FOR PRODUCTION OF THREE-DIMENSIONAL SHAPED ARTICLE
The present invention provides a method for manufacturing a three-dimensional shaped article and an inset for production of a three-dimensional shaped article which make it possible to produce a three-dimensional shaped article with good shaping precision, even when producing a three-dimensional shaped article that has a complex shape and that is made from a soft material, for example. The present invention relates to a method for manufacturing a three-dimensional shaped article, said method comprising: a step for respectively discharging (a) a model material ink which contains a photo-crosslinkable polymer and (b) a support material ink which contains a support material and a first crosslinking factor; a step for photo-curing the discharged photo-crosslinkable polymer; and a step for removing a molded article of the support material ink.
B29C 64/40 - Structures de support des objets en 3D pendant la fabrication, lesdites structures devant être sacrifiées après réalisation de la fabrication
B29C 64/112 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p.ex. dépôt d’un cordon continu de matériau visqueux utilisant des gouttelettes individuelles, p.ex. de buses de jet
The present invention addresses the problem of providing a compound and pharmaceutical composition that possesses inhibitory activity against the drug efflux pumps of drug-resistant bacteria and, when used in combination with another drug, can restore the antibacterial activity of said other drug. The present invention provides a compound represented by general formula [1] (the symbols are as defined in the description) or a salt thereof and a pharmaceutical compound comprising these.
C07D 211/34 - Composés hétérocycliques contenant des cycles pyridiques hydrogénés, non condensés avec d'autres cycles avec uniquement des atomes d'hydrogène et de carbone liés directement à l'atome d'azote du cycle ne comportant pas de liaison double entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone du cycle avec des radicaux hydrocarbonés substitués liés aux atomes de carbone du cycle avec des radicaux hydrocarbonés, substitués par des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p.ex. radicaux ester ou nitrile
A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p.ex. rifampine, thiothixène
C07D 211/14 - Composés hétérocycliques contenant des cycles pyridiques hydrogénés, non condensés avec d'autres cycles avec uniquement des atomes d'hydrogène et de carbone liés directement à l'atome d'azote du cycle ne comportant pas de liaison double entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone du cycle avec des radicaux ne contenant que des atomes de carbone et d'hydrogène liés aux atomes de carbone du cycle avec des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés à l'atome d'azote du cycle
C07D 211/22 - Composés hétérocycliques contenant des cycles pyridiques hydrogénés, non condensés avec d'autres cycles avec uniquement des atomes d'hydrogène et de carbone liés directement à l'atome d'azote du cycle ne comportant pas de liaison double entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone du cycle avec des radicaux hydrocarbonés substitués liés aux atomes de carbone du cycle avec des radicaux hydrocarbonés, substitués par des atomes d'oxygène ou de soufre liés par des liaisons simples par des atomes d'oxygène
C07D 211/26 - Composés hétérocycliques contenant des cycles pyridiques hydrogénés, non condensés avec d'autres cycles avec uniquement des atomes d'hydrogène et de carbone liés directement à l'atome d'azote du cycle ne comportant pas de liaison double entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone du cycle avec des radicaux hydrocarbonés substitués liés aux atomes de carbone du cycle avec des radicaux hydrocarbonés, substitués par des atomes d'azote
C07D 211/46 - Atomes d'oxygène liés en position 4 comportant un atome d'hydrogène comme second substituant en position 4
C07D 211/48 - Atomes d'oxygène liés en position 4 comportant un atome de carbone acyclique lié en position 4
C07D 211/62 - Atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p.ex. radicaux ester ou nitrile liés en position 4
C07D 211/70 - Composés hétérocycliques contenant des cycles pyridiques hydrogénés, non condensés avec d'autres cycles avec uniquement des atomes d'hydrogène et de carbone liés directement à l'atome d'azote du cycle comportant une liaison double entre chaînons cycliques ou entre chaînon cyclique et chaînon non cyclique avec uniquement des atomes d'hydrogène, des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone du cycle
C07D 213/36 - Radicaux substitués par des atomes d'azote liés par des liaisons simples
C07D 277/28 - Radicaux substitués par des atomes d'azote
C07D 305/08 - Composés hétérocycliques contenant des cycles à quatre chaînons comportant un atome d'oxygène comme unique hétéro-atome du cycle non condensés avec d'autres cycles ne comportant pas de liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des hétéro-atomes ou avec des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p.ex. radicaux ester ou nitrile, liés directement aux atomes du cycle
C07D 307/52 - Radicaux substitués par des atomes d'azote ne faisant par partie d'un radical nitro
C07D 307/79 - Benzo [b] furannes; Benzo [b] furannes hydrogénés avec uniquement des atomes d'hydrogène, des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone de l'hétérocycle
C07D 319/18 - Ethylènedioxybenzènes, non substitués sur l'hétérocycle
C07D 333/20 - Radicaux substitués par des hétéro-atomes, autres que les halogènes, liés par des liaisons simples par des atomes d'azote
C07D 401/06 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
C07D 401/10 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles aromatiques
C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 405/06 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
C07D 405/12 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 409/06 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
C07D 409/10 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles aromatiques
C07D 409/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 417/06 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
C07D 417/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
An aortic aneurysm has few noticeable symptoms and is at high risk of rupture without a sign of abnormality. Further, if the aortic aneurysm ruptures, it causes a shock state due to massive blood loss and results in a very low survival rate. Thus, when the aortic aneurysm is found by physical examination or the like, surgery with a stent graft or the like needs to be performed according to the state of its progression.
An aortic aneurysm has few noticeable symptoms and is at high risk of rupture without a sign of abnormality. Further, if the aortic aneurysm ruptures, it causes a shock state due to massive blood loss and results in a very low survival rate. Thus, when the aortic aneurysm is found by physical examination or the like, surgery with a stent graft or the like needs to be performed according to the state of its progression.
A pharmaceutical composition for preventing and treating an aortic aneurysm including a medium chain fatty acid as a main component has an effect of inhibiting the occurrence and progression of the aortic aneurysm. Thus, when the aortic aneurysm is found, continuous intake of the composition can not only inhibit the progression of the aortic aneurysm but also mediate the regression of the aortic aneurysm, thereby producing the effect of improving vital prognosis.
Intracardiac catheters; intravenous catheters; balloon catheters for use in angioplasty; catheters; endoscopes for medical purposes; angioscopes; forceps for medical purposes; endoscopic apparatus for medical purposes; endoscopic equipment for medical purposes; angioscopic apparatus for medical purposes; ultrasound apparatus for medical purposes
48.
SIGNAL DETECTION DEVICE AND SIGNAL DETECTION METHOD
The purpose of the present invention is to simplify the configuration of a signal detection device. The signal detection device (100) comprises: a resonant tunneling diode (RTD) that emits terahertz waves at an object (TG), and receives the terahertz waves reflected by the object (TG) and thereby outputs an output signal; a detection unit (20A) for detecting the output signal from the RTD (1); and a voltage supply unit (11A) for supplying an AC voltage and a DC voltage to the RTD (1).
G01S 7/4911 - DÉTERMINATION DE LA DIRECTION PAR RADIO; RADIO-NAVIGATION; DÉTERMINATION DE LA DISTANCE OU DE LA VITESSE EN UTILISANT DES ONDES RADIO; LOCALISATION OU DÉTECTION DE LA PRÉSENCE EN UTILISANT LA RÉFLEXION OU LA RERADIATION D'ONDES RADIO; DISPOSITIONS ANALOGUES UTILISANT D'AUTRES ONDES - Détails des systèmes correspondant aux groupes , , de systèmes selon le groupe - Détails des systèmes non pulsés Émetteurs
G01N 21/3581 - Couleur; Propriétés spectrales, c. à d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p.ex. spectrométrie d'absorption atomique en utilisant la lumière infrarouge en utilisant un rayonnement térahertz
G01S 13/89 - Radar ou systèmes analogues, spécialement adaptés pour des applications spécifiques pour la cartographie ou la représentation
G01S 17/89 - Systèmes lidar, spécialement adaptés pour des applications spécifiques pour la cartographie ou l'imagerie
H03B 7/08 - Production d'oscillations au moyen d'un élément actif ayant une résistance négative entre deux de ses électrodes avec un élément déterminant la fréquence comportant des inductances et des capacités localisées l'élément actif étant un dispositif à semi-conducteurs l'élément actif étant une diode tunnel
49.
METHOD FOR CHARACTERIZING MOLECULE DELIVERY PARTICLES
An objection is to provide a method for characterizing a molecule delivery particle, the method comprising determining a molar concentration thereof.
An objection is to provide a method for characterizing a molecule delivery particle, the method comprising determining a molar concentration thereof.
The method for characterizing a molecule delivery particle, the method comprising subjecting a molecule delivery particle comprising a first particle and a second particle to particle separation with optical measurement to determine an increment in refractive index of each of the first particle and the second particle; and determining a molar concentration of each of the first particle and the second particle based on the increment in refractive index, a molecular weight, and a specific refractive index increment of each of the first particle and the second particle.
G01N 21/33 - Couleur; Propriétés spectrales, c. à d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p.ex. spectrométrie d'absorption atomique en utilisant la lumière ultraviolette
G16B 40/10 - Traitement du signal, p.ex. de spectrométrie de masse ou de réaction en chaîne par polymérase
50.
SEMICONDUCTOR NANOPARTICLE, METHOD FOR MANUFACTURING SAME, AND LIGHT EMITTING DEVICE
National University Corporation Tokai National Higher Education and Research System (Japon)
OSAKA UNIVERSITY (Japon)
NICHIA CORPORATION (Japon)
Inventeur(s)
Torimoto, Tsukasa
Kameyama, Tatsuya
Mori, Yuki
Yamauchi, Hiroki
Kuwabata, Susumu
Uematsu, Taro
Oyamatsu, Daisuke
Abrégé
Provided is a method for manufacturing a semiconductor nanoparticle, the method includes performing a heat treatment of a first mixture containing a silver (Ag) salt, an alkali metal salt, a salt containing at least one of indium (In) and gallium (Ga), a sulfur source, and an organic solvent. A ratio of the number of atoms of an alkali metal to the total number of atoms of Ag and the alkali metal in the first mixture is greater than 0 and less than 1.
H01L 33/06 - DISPOSITIFS À SEMI-CONDUCTEURS NON COUVERTS PAR LA CLASSE - Détails caractérisés par les corps semi-conducteurs ayant une structure à effet quantique ou un superréseau, p.ex. jonction tunnel au sein de la région électroluminescente, p.ex. structure de confinement quantique ou barrière tunnel
B82Y 15/00 - Nanotechnologie pour l’interaction, la détection ou l'actionnement, p.ex. points quantiques comme marqueurs en dosages protéiques ou moteurs moléculaires
B82Y 40/00 - Fabrication ou traitement des nanostructures
H01L 33/00 - DISPOSITIFS À SEMI-CONDUCTEURS NON COUVERTS PAR LA CLASSE - Détails
51.
External Preparation for Treating Epilepsy or Autism Spectrum Disorder
[Object] It is an object to provide a highly safe and easy-to-administer pharmaceutical preparation for treating epilepsy, pharmaceutical preparation for treating an autism spectrum disorder, and/or pharmaceutical preparation for treating an anxiety disorder. [Solving Means] A topical preparation containing as an active ingredient at least one selected from the group consisting of sirolimus and a sirolimus derivative is a pharmaceutical preparation that is easy to administer, and is highly safe as a therapeutic agent for epilepsy, an autism spectrum disorder, and/or an anxiety disorder. Suitable examples of the active ingredient include sirolimus, everolimus, temsirolimus, ridaforolimus, and zotarolimus.
A61K 31/675 - Composés du phosphore ayant l'azote comme hétéro-atome d'un cycle, p.ex. phosphate de pyridoxal
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p.ex. rapamycine
A61K 47/10 - Alcools; Phénols; Leurs sels, p.ex. glycérol; Polyéthylène glycols [PEG]; Poloxamères; Alkyléthers de PEG/POE
An optical module according to the present embodiment includes: a first lens array unit in which a plurality of first lenses configured to collect irradiating light are arranged; a second lens array unit which includes a plurality of second lenses and on which signal light from the first lenses is incident; and a plurality of beam splitters configured to reflect irradiating light to the first lenses and to transmit the signal light from the first lenses, wherein reflectance of the beam splitter on a nearest side in a travel direction of the irradiating light is set lowest and the more toward a far side in the travel direction, the higher the reflectance of the beam splitters.
G01N 21/31 - Couleur; Propriétés spectrales, c. à d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p.ex. spectrométrie d'absorption atomique
The present disclosure includes a composition for use in the treatment of dystrophic epidermolysis bullosa, comprising a blister-derived cell of a patient with dystrophic epidermolysis bullosa that is genetically modified to produce type VII collagen.
An apparatus (1) includes an exercise sensor (31) that continuously detects a movement of an exerciser accompanied by intermittent exercise, and a heart rate meter (32) that continuously measures a heart rate of the exerciser, and further includes an activity detection unit (12), a heart rate monitoring unit (13), an activity monitoring unit (14), and a notification processing unit (15). The activity detection unit (12) detects, from the movement of the exerciser, an activity intensity, a high activity intensity period, and a low activity intensity period. The heart rate monitoring unit (13) detects a declining trend in the heart rate of the exerciser, in the low activity intensity period each time, and monitors whether or not the declining trend of this time is low as compared with a predetermined reference. The activity monitoring unit (14), in a case in which the monitoring by the heart rate monitoring unit is affirmed, monitors whether or not the activity intensity to be detected in the high activity intensity period of a next time is low as compared with activity intensities detected in high activity intensity periods up to a previous time. The notification processing unit (15), in a case in which the monitoring by the activity monitoring unit is affirmed, forecasts an outbreak of disease. With this configuration, the outbreak of disease in an exerciser during an exercise is forecasted with higher accuracy.
G16H 50/80 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour la détection, le suivi ou la modélisation d’épidémies ou des pandémies, p.ex. de la grippe
A61B 5/0205 - Evaluation simultanée de l'état cardio-vasculaire et de l'état d'autres parties du corps, p.ex. de l'état cardiaque et respiratoire
A61B 5/024 - Mesure du pouls ou des pulsations cardiaques
A61B 5/11 - Mesure du mouvement du corps entier ou de parties de celui-ci, p.ex. tremblement de la tête ou des mains ou mobilité d'un membre
55.
Pharmaceuticals That Promote Functional Regeneration of Damaged Tissues
The present inventors revealed the following for the first time in the world:
1) a large amount of bone marrow-derived cells are mobilized to grafted skin;
2) the mobilized bone marrow-derived cells are differentiated into any of dermal fibroblasts, adipocytes, muscle cells, vascular endothelial cells, and epidermal keratinocytes in the grafted skin, and the mobilized bone marrow-derived cells include bone marrow-derived mesenchymal stem cells;
3) the factors which mobilize bone marrow-derived mesenchymal stem cells from peripheral blood to the grafted skin are HMGB1, HMGB2, and HMGB3 released from the necrosed tissue of recipient skin;
4) purified HMGB1, HMGB2, and HMGB3 promote the migration of mesenchymal stem cells isolated and cultured from bone marrow;
5) activators containing HMGB1 which allows the migration of bone marrow mesenchymal stem cells can be conveniently purified from several organ extracts including skin, brain, and heart;
6) activators which allow the migration of bone marrow mesenchymal stem cells can be conveniently extracted from cultured cells; and
7) a heparin-column purified fraction of skin extract mobilizes a large amount of bone marrow-derived cells in case of brain injury.
A61K 31/711 - Acides désoxyribonucléiques naturels, c. à d. contenant uniquement des 2'-désoxyriboses liés à l'adénine, la guanine, la cytosine ou la thymine et ayant des liaisons 3'-5' phosphodiester
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
56.
FRICTION STIR WELDING METHOD AND FRICTION STIR WELDING TOOL
This friction stir welding method causes a friction stir welding tool to pass through a material to be welded, in the thickness direction of the material to be welded, and performs friction stir welding in a state in which a refrigerant is flowing through a through-hole provided in a rotating shaft of the friction stir welding tool.
B23K 20/12 - Soudage non électrique par percussion ou par une autre forme de pression, avec ou sans chauffage, p.ex. revêtement ou placage la chaleur étant produite par friction; Soudage par friction
57.
METHOD FOR CULTURING CANCER ORGANOID AND METHOD FOR SCREENING TEST SUBSTANCE
This method for culturing a cancer organoid includes culturing the cancer organoid on the top surface or inside of a cell structure in a medium free from extracellular matrix, wherein the cell structure contains cells constituting the stroma and two or more cell layers are laminated in the thickness direction therein. The method for screening a test substance includes culturing a cell structure containing a cancer organoid, which is obtained by the aforesaid method for culturing a cancer organoid, in the presence of a test substance, and evaluating the effect of the test substance on the cancer organoid.
C12N 1/00 - Micro-organismes, p.ex. protozoaires; Compositions les contenant; Procédés de culture ou de conservation de micro-organismes, ou de compositions les contenant; Procédés de préparation ou d'isolement d'une composition contenant un micro-organisme; Leurs milieux de culture
C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des micro-organismes viables
According to an embodiment, the present disclosure provides a modified luciferase having improved luminescence intensity, and a use thereof. The present disclosure relates to a modified luciferase derived from a luminous mushroom, or a functional fragment thereof in which a mutation is introduced into at least one among arginine or lysine corresponding to position 26 and valine corresponding to position 161 in the amino acid sequence indicated by SEQ ID NO: 1, and which has an enhanced luminescence compared with the luminescence before the introduction of the mutation. The present disclosure also relates to an isolated nucleic acid encoding the modified luciferase or a functional fragment thereof.
A01H 5/00 - Angiospermes, c. à d. plantes à fleurs, caractérisées par leurs parties végétales; Angiospermes caractérisées autrement que par leur taxonomie botanique
C12N 15/31 - Gènes codant pour des protéines microbiennes, p.ex. entérotoxines
C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
59.
CATHETER SIMULATOR AND HEART MODEL FOR CATHETER SIMULATOR
A heart model includes a main body formed from an elastic material and including a left atrium and a left ventricle, with a mitral valve installed at a boundary portion between the left atrium and the left ventricle; and a vena cava provided in the main body, wherein the mitral valve includes an anterior leaflet and a posterior leaflet, both the leaflets extending to the left ventricle side and capable of opening and closing, and the anterior leaflet and the posterior leaflet are each provided on a tip side with a plurality of string-shaped members extending into the left ventricle.
[Problem] To provide a high precision sensor having a simpler structure. [Solution] According to one aspect of the present invention, a sensor for measuring objects is provided. The sensor comprises a plurality of light-emitting elements and at least one light-receiving element. The light-emitting elements are each provided at a different position on a substrate. The light-receiving element is provided on the substrate. The light-receiving element receives, as main light, one reflected light from among reflected light attributed to each light-emitting element, and receives, as crosstalk light, reflected light other than the main light in a manner such that the crosstalk light can be distinguished from the main light. The reflected light is emitted from each of the light-emitting elements and reflected from an object. On the basis of the crosstalk light and main light that are received in a distinguishable manner, spatial physical quantities related to a reference plane of the sensor and the object are measured.
The present invention addresses the problem of providing a novel composition for cartilage repair including cells that have characteristics suitable for cartilage repair, and a method for producing same. With a focus on umbilical cord tissue-derived cells, three-dimensional culturing of umbilical cord tissue-derived cells was carried out. It was found that umbilical cord tissue-derived cells constituting a culture obtained by three-dimensional culturing have cell proliferation ability and gene expression level characteristics different from those of cells constituting a culture obtained by three-dimensional culturing of cells derived from other tissues. The umbilical cord tissue-derived cells constituting a culture obtained by three-dimensional culturing of the present invention have characteristics suitable for cartilage repair and make it possible to provide a composition effective for cartilage repair.
It was found that administering a composition containing cancer cells that express damage-associated molecular patterns (DAMPs) to a subject using a needleless syringe causes the cancer cells in the composition to be damaged by shear force at the time of administration and the DAMPs to be released from the cells, whereby cell-mediated immunity is efficiently activated.
STROOP TEST METHOD, STROOP TEST PROGRAM, STROOP TEST SYSTEM, STROOP TEST IMAGE GENERATION METHOD, STROOP TEST IMAGE GENERATION PROGRAM, AND TEST METHOD
In this Stroop test method, an evaluation of a subject is indicated on the basis of line-of-sight position information indicating the position of the line-of-sight of the subject in a test image (S102-S105). The test image has a question region in which a question for the subject is displayed, and an answer region in which a plurality of options for the subject to select to answer the question by means of the line-of-sight are displayed, the plurality of options including a correct option and one or more incorrect options. The one or more incorrection options include a decoy option that a subject may be guided to by the Stroop effect.
A61B 10/00 - Autres méthodes ou instruments pour le diagnostic, p.ex. pour le diagnostic de vaccination; Détermination du sexe; Détermination de la période d'ovulation; Instruments pour gratter la gorge
A61B 3/113 - Appareils pour l'examen optique des yeux; Appareils pour l'examen clinique des yeux du type à mesure objective, c. à d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient pour déterminer ou enregistrer le mouvement de l'œil
G06F 3/01 - Dispositions d'entrée ou dispositions d'entrée et de sortie combinées pour l'interaction entre l'utilisateur et le calculateur
G06F 3/0346 - Dispositifs de pointage déplacés ou positionnés par l'utilisateur; Leurs accessoires avec détection de l’orientation ou du mouvement libre du dispositif dans un espace en trois dimensions [3D], p.ex. souris 3D, dispositifs de pointage à six degrés de liberté [6-DOF] utilisant des capteurs gyroscopiques, accéléromètres ou d’inclinaiso
64.
INORGANIC STRUCTURE AND METHOD FOR PRODUCING INORGANIC STRUCTURE
Provided are an inorganic structure including portions differing in mechanical property and a method for producing the inorganic structure. An inorganic structure (1) as an embodiment of the present invention comprises a plurality of solidified portions (SA) made of an inorganic material. The plurality of solidified portions (SA) comprise a first solidified portion (SA1), in which the material has been oriented preferentially in a first crystallographic orientation (CO1), and a second solidified portion (SA2), in which the material has been oriented preferentially in a second crystallographic orientation (CO2), which differs from the first crystallographic orientation (CO1).
B22F 10/38 - Commande ou régulation des opérations pour obtenir des caractéristiques spécifiques du produit, p.ex. le lissage de la surface, la densité, la porosité ou des structures creuses
B22F 10/28 - Fusion sur lit de poudre, p.ex. fusion sélective par laser [FSL] ou fusion par faisceau d’électrons [EBM]
B28B 1/30 - Fabrication d'objets façonnés à partir du matériau en appliquant le matériau sur un noyau ou une autre surface de moulage pour former une couche sur celle-ci
An object of the present invention is to provide a novel method for producing a ketone derivative, and more specifically, a method for producing a ketone derivative (I) represented by formula (I), including mixing a thioester derivative (II) represented by formula (II), a Grignard reagent (III) represented by formula (III) and a copper salt to form a ketone derivative (I).
C07D 333/22 - Radicaux substitués par des hétéro-atomes liés par une liaison double ou par deux hétéro-atomes, autres que des halogènes, liés au même atome de carbone par des liaisons simples
C07C 45/51 - Préparation de composés comportant des groupes C=O liés uniquement à des atomes de carbone ou d'hydrogène; Préparation des chélates de ces composés par pyrolyse, réarrangement ou décomposition
C07C 45/54 - Préparation de composés comportant des groupes C=O liés uniquement à des atomes de carbone ou d'hydrogène; Préparation des chélates de ces composés par pyrolyse, réarrangement ou décomposition de composés contenant des atomes d'oxygène liés par des liaisons doubles, p.ex. d'esters
C07C 67/317 - Préparation d'esters d'acides carboxyliques par modification de la partie acide de l'ester sans introduction d'un groupe ester par hydrogénolyse de groupes fonctionnels
C07C 253/30 - Préparation de nitriles d'acides carboxyliques par des réactions n'impliquant pas la formation de groupes cyano
66.
CATHETER SIMULATOR AND CEREBRAL BLOOD VESSEL MODEL
A catheter simulator includes a container capable of accommodating a liquid in an accommodation part surrounded by side walls and a bottom part; a cerebral blood vessel model held in the container in a state of accommodating a liquid; a pump connected to the container and circulating the liquid inside the cerebral blood vessel model held therein; and a holder provided on the side walls of the container and the cerebral blood vessel model and holding the cerebral blood vessel model in a state of having the container filled with the liquid, wherein the holder includes a first holding part holding an end of an ascending aorta of the cerebral blood vessel model, and a second holding part holding an end of a descending aorta of the cerebral blood vessel model.
G09B 23/34 - Modèles anatomiques avec des parties amovibles
67.
SYSTEM FOR DETERMINING DEPRESSION RISK USING FUNDUS IMAGE, MACHINE LEARNING MODEL GENERATION DEVICE, DEPRESSION RISK DETERMINATION DEVICE, AND DEPRESSION RISK DETERMINATION METHOD
Provided is a depression risk determining system with which it is possible to determine the risk of depression from a fundus image. The system for determining depression risk according to the present invention comprises: a machine learning model generation device that generates a trained model for determining the risk of depression; and a depression risk determination device that determines the risk of depression by using the trained model generated by the machine learning model generation device. The machine learning model generation device includes a data acquisition unit that acquires at least inquiry data for training and a fundus image for training, and a machine learning model generation unit that generates a trained model. The depression risk determination device includes a determination data acquisition unit that acquires a fundus image used for determination, a depression risk determination unit that inputs at least the fundus image used for determination to the trained model to thereby output a prediction score indicating depression risk, and a determination result output unit that outputs the determination results of depression risk on the basis of the prediction score.
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
To develop a new tumor preventative/therapeutic. Provided are: an agent for preventing and/or treating a tumor, the agent containing, inter alia, an IKZF1ΔE5 protein, which is a deletion variant of IKZF1 in which part or all of exon 5 has been deleted, or an IKZF1ΔE5-gene-related substance; and a method for screening such agents.
A61K 38/17 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains
A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
A61K 35/17 - Lymphocytes; Lymphocytes B; Lymphocytes T; Cellules tueuses naturelles; Lymphocytes activés par un interféron ou une cytokine
A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
G01N 33/53 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet
69.
AROMATIC COMPOUND, MIXTURE, MOLECULAR PROBE FOR HYPERPOLARIZATION, METABOLITE, DIAGNOSTIC AGENT, DERIVATIZATION AGENT, NAPHTHALENE DERIVATIVE, CATECHOL DERIVATIVE, AND COMPOUND
An aromatic compound configured from a stable isotope, wherein two adjacent carbon atoms are 13C, the nuclear spin quantum number of the other atoms to which the two adjacent carbon atoms bond is 0, and a hydrogen atom that has a spin coupling constant and bonds with the 13C nucleus via a carbon atom is substituted with a deuterium atom. In this aromatic compound, the relaxation time of the 13C nucleus excited by a DNP device is longer than in the past.
A61K 31/136 - Amines, p.ex. amantadine ayant des cycles aromatiques, p.ex. méthadone ayant le groupe amino lié directement au cycle aromatique, p.ex. benzène-amine
A61K 31/192 - Acides carboxyliques, p.ex. acide valproïque ayant des groupes aromatiques, p.ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
C07B 59/00 - Introduction d'isotopes d'éléments dans les composés organiques
C07C 11/22 - Hydrocarbures non saturés acycliques comportant des liaisons triples carbone-carbone
C07C 33/34 - Alcools monohydroxyliques contenant des cycles aromatiques à six chaînons et d'autres cycles
C07C 47/12 - Composés saturés comportant des groupes —CHO liés à des atomes de carbone acycliques ou à de l'hydrogène contenant plus d'un groupe —CHO
C07C 211/58 - Naphtylamines; Leurs dérivés N-substitués
C07C 229/36 - Composés contenant des groupes amino et carboxyle liés au même squelette carboné ayant des groupes amino et carboxyle liés à des atomes de carbone acycliques du même squelette carboné le squelette carboné contenant des cycles aromatiques à six chaînons avec au moins un groupe amino et un groupe carboxyle liés au même atome de carbone du squelette carboné
C07C 255/04 - Nitriles d'acides carboxyliques ayant des groupes cyano liés à des atomes de carbone acycliques d'un squelette carboné acyclique et saturé contenant deux groupes cyano liés au squelette carboné
The purpose of the present invention is to provide a method for manufacturing a layered structure in which it is easy to control the crystal structure in the layered structure. A method for manufacturing a layered structure is selected in which: a gas flow parallel to the surface of a powder bed is provided; an energy beam is radiated while being scanned in a first direction to form a first melt-solidified layer; an energy beam is radiated while being scanned in a second direction intersecting the first direction to form a second melt-solidified layer; a first accumulation thickness of the powder bed and a first heat input amount of the energy beam are adjusted to control the layering thickness of the first melt-solidified layer and the penetration depth of the first melt-solidified layer; a second accumulation thickness of the powder bed and a second heat input amount of the energy beam are adjusted to control the layering thickness of the second melt-solidified layer and the penetration depth of the second melt-solidified layer; the angle α1 between the first direction and the gas flow direction is adjusted to control the first heat input amount; the angle α2 between the second direction and the gas flow direction is adjusted to control the second heat input amount; and the residual thickness of the first melt-solidified layer and the residual thickness of the second melt-solidified layer in the crystal structure are controlled.
B22F 10/322 - Commande ou régulation des opérations de l’atmosphère, p.ex. de la composition ou de la pression dans une chambre de fabrication d’un écoulement de gaz, p.ex. du débit ou de la direction
B22F 10/28 - Fusion sur lit de poudre, p.ex. fusion sélective par laser [FSL] ou fusion par faisceau d’électrons [EBM]
B22F 10/366 - Paramètres de balayage, p.ex. distance d’éclosion ou stratégie de balayage
B22F 10/38 - Commande ou régulation des opérations pour obtenir des caractéristiques spécifiques du produit, p.ex. le lissage de la surface, la densité, la porosité ou des structures creuses
An evaluation method is performed by an arithmetic circuit and includes obtainment processing (S1), evaluation processing (S2), and presentation processing (S3). The obtainment processing (S1) obtains: image information on a sectional image representing an interested section of an organism including a target section of a testis of the organism generated by use of magnetic resonance of hydrogen atoms; and concentration information on a creatine concentration in the interested section measured by use of magnetic resonance based on chemical exchange saturation transfer. The evaluation processing (S2) generates an evaluation image representing a distribution of evaluation results of a testicular function in the target section based on the concentration information. The presentation processing (S3) presents the sectional image and the evaluation image.
A61B 5/055 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiques; Mesure utilisant des micro-ondes ou des ondes radio faisant intervenir la résonance magnétique nucléaire [RMN] ou électronique [RME], p.ex. formation d'images par résonance magnétique
G01R 33/485 - Systèmes d'imagerie RMN avec sélection de signaux ou de spectres de régions particulières du volume, p.ex. spectroscopie in vivo basés sur l'information de déplacement chimique
A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
Provided is a method for producing high-quality group III nitride crystals through a flux method. This method for producing group III nitride crystals includes bringing a melt that includes an alkali metal and at least one group III element selected from gallium, aluminum, and indium into contact with the surface of group III nitride seed crystals in a nitrogen-containing atmosphere, thereby reacting the group III element and nitrogen within the melt to grow group III nitride crystals on the group III nitride seed crystals, wherein: the method includes a nucleus generation step for growing a plurality of island-form group III nitride crystal nuclei on the surface of group III nitride seed crystals, a first crystal growth step for growing first group III nitride crystals, each of which has an inverted triangular or trapezoidal cross-section, from the plurality of island-form group III nitride crystal nuclei, and a second crystal growth step for growing second group III nitride crystals so that hollows in the first group III nitride crystals are filled and the surface becomes flat; in the nucleus generation step for growing a plurality of island-form group III nitride crystal nuclei, the temperature is 875°C or higher, and the nucleus generation density is 1×106/cm2 or lower; and the first and second crystal growth steps include repeatedly immersing the group III nitride seed crystals in the melt and lifting the group III nitride seed crystals from the melt a plurality of times.
C30B 19/04 - Croissance d'une couche épitaxiale à partir de la phase liquide en utilisant des solvants fondus, p.ex. des fondants le solvant étant un constituant du cristal
Intracardiac catheters; Intravenous catheters; Medical catheters; Endoscopes for medical purposes; Forceps for medical use; Diagnostic apparatus for medical purposes, namely, processing apparatus for medical imaging devices, angiographic catheters, angioscopes, and forceps; Surgical apparatus and instruments, namely, processing apparatus for medical imaging devices, angiographic catheters, cardiac catheters, angioscopes, cardiac pacing instruments, medical guidewires, blood pressure interfaces and analyzers, and balloon inflation devices; Therapeutic apparatus and instruments, namely, processing apparatus for medical imaging devices, angiographic catheters, cardiac catheters, angioscopes, pacemakers, and cardiac prosthetics; Medical apparatus and instruments, namely, processing apparatus for medical imaging devices, angiographic catheters, cardiac catheters, angioscopes, cardiac pacing instruments, medical guidewires, blood pressure interfaces and analyzers, balloon inflation devices, pacemakers, and cardiac prosthetics
A biosensor is a field-effect transistor-based biosensor including an insulating substrate, and a measurement sensor and a reference sensor on the insulating substrate. A probe molecule is in the measurement sensor. The probe molecule has a first basic moiety in the measurement sensor, and a recognition moiety with a first end bound to the first basic moiety and a second end defining a distal end of the probe molecule. A second basic moiety is in the reference sensor and has a same structure as that of the first basic moiety of the probe molecule in the measurement sensor. The recognition moiety of the probe molecule in the measurement sensor is absent at the distal end of the second basic moiety.
[Problem] A mineralocorticoid receptor (MR) is activated due to various pathoses, and the excessive activation thereof is a risk factor of the onset of cerebrocardiovascular diseases. However, since there are no indicators for directly evaluating MR activity, the early detection of excessive MR activation is difficult. The present invention addresses the problem of finding out indicators capable of directly evaluating MR activity. [Solution] It has been found that MR activity can be directly evaluated by using, as an indicator, the protein amount in an epithelial sodium channel (ENaC) subunit contained in a urinary extracellular vesicle. The indicator is preferably the ratio of the protein amount in the ENaC subunit to the internal control protein amount in the extracellular vesicle. The ratio (γENaC/CD9) of ENaCγ subunit to CD9 is exemplified as a specific aspect thereof. Using the indicator makes it possible to start early treatment by examining diseases related to MR activation. The start of early treatment makes it possible to prevent the onset of cerebrocardiovascular diseases.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 33/74 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des hormones
76.
METHOD FOR CHECKING POSSIBILITY OF LIVER CANCER ONSET
Provided is a method for checking the possibility of liver cancer onset. This method for checking the possibility of liver cancer onset comprises (1) a step for detecting at least one type of molecules of interest selected from the group consisting of Fibulin 3, GPNMB, Fibulin 3 mRNA, and GPNMB mRNA in a biological sample collected from a subject.
G01N 33/574 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour le cancer
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
77.
PREDICTION DEVICE, PREDICTION METHOD, AND PREDICTION PROGRAM
NATIONAL INSTITUTES FOR QUANTUM SCIENCE AND TECHNOLOGY (Japon)
OSAKA UNIVERSITY (Japon)
Inventeur(s)
Majima, Kei
Yahata, Noriaki
Yanagisawa, Takufumi
Fukuma, Ryohei
Kishima, Haruhiko
Shiraishi, Yoshiyuki
Kawahara, Yoshinobu
Yamashita, Okito
Abrégé
Provided are a prediction device, a prediction method, and a prediction program that can make predictions from multidimensional time series data at high speed and with high accuracy. A prediction device 1, which analyzes multidimensional time series data regarding a predetermined event, and predicts events from the multidimensional time series data, includes a predictive means for acquiring multidimensional time series data, decomposes the multidimensional time series data into matrix data using dynamic mode decomposition, acquires features from the matrix data, acquires predicted values from the features and weights calculated in advance on the basis of the kernel method, and predicts events from the predicted values.
NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY (Japon)
OSAKA UNIVERSITY (Japon)
Inventeur(s)
Yokota Takanori
Yoshioka Kotaro
Matsubayashi Taiki
Obika Satoshi
Nakagawa Osamu
Abrégé
The present invention addresses the problem of providing a novel nucleic acid drug capable of simultaneously achieving both a high gene regulatory effect and a low toxicity. Provided is a toxicity reducing agent for a nucleic acid drug that comprises a nucleoside containing an artificial base represented by formula (I), said toxicity reducing agent being linked to a nucleic acid chain constituting the nucleic acid drug via an internucleoside linkage.
A61K 31/7068 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p.ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p.ex. cytidine, acide cytidylique
A61K 31/7115 - Acides nucléiques ou oligonucléotides ayant des bases modifiées, c. à d. autres que l'adénine, la guanine, la cytosine, l'uracile ou la thymine
A61K 31/712 - Acides nucléiques ou oligonucléotides ayant des sucres modifiés, c. à d. autres que le ribose ou le 2'-désoxyribose
A61K 31/7125 - Acides nucléiques ou oligonucléotides ayant des liaisons internucléosides modifiées, c. à d. autres que des liaisons 3'-5' phosphodiester
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p.ex. acides nucléiques avec le désoxyribosyle comme radical saccharide
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITION (Japon)
Inventeur(s)
Mizuguchi Hiroyuki
Sakurai Fuminori
Kamada Haruhiko
Abrégé
Provided is a human Ad 5 vector etc., capable of avoiding immune response by existing antibody. The present invention is based on human adenovirus type 5 and pertains to a hexon-modified adenovirus vector in which the amino acid sequence of at least one hypervariable region (HVR) among HVR1 through HVR7 present in the hexon region has been modified.
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p.ex. antidiabétiques
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61P 31/00 - Agents anti-infectieux, c. à d. antibiotiques, antiseptiques, chimiothérapeutiques
The present invention provides a method for manufacturing a three-dimensional object and an ink set for manufacturing a three-dimensional object, whereby it is possible to manufacture a three-dimensional object with good modeling accuracy, for example, even when manufacturing a complex-shaped three-dimensional object made of soft materials. The present invention pertains to a method for manufacturing a three-dimensional object, the method comprising the steps of: discharging (a) a modelling material ink containing a crosslinkable polymer and (b) a support material ink containing a support material, respectively; and removing an object from the support material ink after crosslinking the crosslinkable polymer, wherein either one of the modelling material ink (a) and the support material ink (b) further contains a hydrogen peroxide decomposer, the other further contains hydrogen peroxide or a hydrogen peroxide donor, and the discharged hydrogen peroxide decomposer decomposes discharged hydrogen peroxide and crosslinks the crosslinkable polymer, thereby creating a three-dimensional object.
B29C 64/112 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p.ex. dépôt d’un cordon continu de matériau visqueux utilisant des gouttelettes individuelles, p.ex. de buses de jet
B29C 64/40 - Structures de support des objets en 3D pendant la fabrication, lesdites structures devant être sacrifiées après réalisation de la fabrication
Provided are: a pharmaceutical composition for treating damage to the white-white zone or red-white zone of the meniscus, said composition containing an HMGB1 fragment peptide containing an amino acid sequence delimited by SEQ ID NO 1, or a variant thereof; and a pharmaceutical composition for treating a meniscus excision site, said composition containing an HMGB1 fragment peptide containing an amino acid sequence delimited by SEQ ID NO 1, or a variant thereof.
A61K 38/16 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés
A61P 19/04 - Médicaments pour le traitement des troubles du squelette des troubles non-spécifiques du tissu conjonctif
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
The present disclosure provides anti-CTLA-4 antibodies and methods of producing and using the antibodies. The present disclosure also provides nucleic acids encoding the anti-CTLA-4 antibodies and host cells containing the nucleic acids. Furthermore, the present disclosure provides polypeptides containing a variant Fc region containing amino acid alterations in a parent Fc region and methods of producing and using the polypeptides.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
83.
VIBRATION COMPONENT MEASURING DEVICE, KELVIN PROBE FORCE SPECTROMETER, VIBRATION COMPONENT MEASURING METHOD, AND INTERFACE STATE DENSITY MEASURING METHOD
In order to measure a change in a fluctuating component of a vibrating unit more efficiently, and to calculate an interface state density of a sample more efficiently, a vibration component measuring device (2) comprises: a vibrating unit (4); a vibration control unit (10) for causing the vibrating unit to vibrate on the basis of a first alternating current signal; a signal applying unit (14, 48) for applying at least one of a direct current signal, a second alternating current signal, and a reference alternating current signal between the vibrating unit and a sample; and a measuring unit (42, 44) for measuring a fluctuating component of the vibration of the vibrating unit. The measuring unit measures a change in the fluctuating component with respect to a change in a voltage value of the direct current signal.
The present invention provides a liposome preparation containing a population of liposomes containing a CD1d ligand compound, wherein the average particle size of the population of liposomes is 90 to 110 nm and the polydispersity index of particle size distribution is 0.2 or less. and the polydispersity index of the particle size distribution is 0.2 or less. The present invention also provides the use of the liposome preparation in the prevention or treatment of graft-versus-host disease and organ transplant rejection.
A61K 31/7032 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un polyol, c. à d. composés ayant plusieurs groupes hydroxyle, libres ou estérifiés, y compris le groupe hydroxyle impliqué dans la liaison glycosidique, p.ex. monoglucosyl-diacylglycérides, acide lactobionique, gangliosides
A heart valve abnormality detection device includes a heart sound data acquisition portion 21 configured to acquire heart sound data corresponding to heart sounds, a first processing portion configured to set, based on the heart sound data, a section between a first heart sound and a second heart sound of the heart sounds as a target range and acquire a peak frequency that is a peak value of a frequency in a frequency component of the heart sounds within the target range, and a second processing portion configured to output a detection signal indicating that there is a high probability of severe aortic stenosis in a case where the peak frequency is a peak reference value or greater.
A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
A61B 5/02 - Mesure du pouls, du rythme cardiaque, de la pression sanguine ou du débit sanguin; Détermination combinée du pouls, du rythme cardiaque, de la pression sanguine; Evaluation d'un état cardio-vasculaire non prévue ailleurs, p.ex. utilisant la combinaison de techniques prévues dans le présent groupe et des techniques d'électrocardiographie; Sondes cardiaques pour mesurer la pression sanguine
86.
ALGINIC ACID SALT AND HEMOSTATIC MATERIAL CONTAINING SAME
A purpose of the present invention is to provide an alginic acid salt superior in hemostatic effect to conventional alginic acid salts. This alginic acid salt has a carboxyl-group calcium salt and another carboxyl (salt) group, and is characterized in that, when structural units containing the calcium salt group, among the repeating units (structural units) constituting the alginic acid salt, are referred to as calcium alginate and structural units containing the other carboxyl (salt) group are referred to as sodium alginate and when the alginic acid salt is regarded as a mixture of the sodium alginate and the calcium alginate, then the mass proportion (calcium content) of the calcium alginate is 1-99 mass%.
To provide a collagen sponge excellent in mechanical strength and a production method for the collagen sponge. A collagen sponge including a porous construct having a pore structure, the collagen sponge having a tensile strength of 1 N or more and 5 N or less in every direction including a length direction and a width direction. The collagen sponge may be produced by a production method including the following steps: (1) a step of subjecting a collagen solution obtained by mixing collagen and a solvent to stirring and deaeration treatment; (2) a step of subjecting the collagen solution to freeze-dry treatment; and (3) a step of subjecting a dried collagen product after the freeze-dry treatment to insoluble treatment.
C08J 9/28 - Mise en œuvre de substances macromoléculaires pour produire des matériaux ou objets poreux ou alvéolaires; Leur post-traitement par élimination d'une phase liquide d'un objet ou d'une composition macromoléculaire, p.ex. par séchage du coagulum
88.
SEMICONDUCTOR NANOPARTICLES AND METHOD OF PRODUCING SEMICONDUCTOR NANOPARTICLES
NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM (Japon)
NICHIA CORPORATION (Japon)
Inventeur(s)
Kuwabata, Susumu
Uematsu, Taro
Wajima, Kazutaka
Torimoto, Tsukasa
Kameyama, Tatsuya
Oyamatsu, Daisuke
Niki, Kenta
Abrégé
A semiconductor nanoparticle includes a core and a shell covering a surface of the core. The shell has a larger bandgap energy than the core and is in heterojunction with the core. The semiconductor nanoparticle emits light when irradiated with light. The core is made of a semiconductor that contains M1, M2, and Z. M1 is at least one element selected from the group consisting of Ag, Cu, and Au. M2 is at least one element selected from the group consisting of Al, Ga, In and Tl. Z is at least one element selected from the group consisting of S, Se, and Te. The shell is made of a semiconductor that consists essentially of a Group 13 element and a Group 16 element.
C09K 11/62 - Substances luminescentes, p.ex. électroluminescentes, chimiluminescentes contenant des substances inorganiques luminescentes contenant du gallium, de l'indium ou du thalium
B01J 13/02 - Fabrication de microcapsules ou de microbilles
C09K 11/02 - Emploi de substances particulières comme liants, revêtements de particules ou milieux de suspension
C09B 67/02 - Préparations tinctoriales caractérisées par un aspect physique particulier, p.ex. tablettes, feuilles
89.
SULFUR-CONTAINING HIGH MOLECULAR WEIGHT COMPOUND AND METHOD FOR PRODUCING SAME, POLYMER COMPOSITION, AND SULFUR-CONTAINING COMPOUND
Provided are a new sulfur-containing polymer and a method for producing the same, a composition containing the new sulfur-containing polymer, and a sulfur-containing compound. A sulfur-containing high molecular weight compound according to the present invention has a structural unit represented by, for example, general formula (1) -R1-R-R1nn- (in formula (1), n represents a number of 1 or more, R represents an organic group, and R1 represents a divalent organic group derived from a functional group that can undergo polycondensation). A method for producing a sulfur-containing high molecular weight compound according to the present invention comprises a step for obtaining the sulfur-containing high molecular weight compound by reacting a linear sulfur polymer and a compound C having two functional groups that can undergo polycondensation.
The purpose of the present invention is to realize a Faraday rotator that is small, inexpensive, and can withstand high-output and high-repetition laser radiation. An optical element (100) includes: a reflective Faraday rotation element (110) that rotates the polarization plane of reflected light with respect to the polarization plane of incident light; a magnet (130) provided on the opposite side of the plane onto which the incident light falls with respect to the Faraday rotation element; and a coolant circulation unit (140) and/or a cryostat (150) that cools the Faraday rotation element.
G02B 27/28 - Systèmes ou appareils optiques non prévus dans aucun des groupes , pour polariser
G02F 1/09 - Dispositifs ou dispositions pour la commande de l'intensité, de la couleur, de la phase, de la polarisation ou de la direction de la lumière arrivant d'une source lumineuse indépendante, p.ex. commutation, ouverture de porte ou modulation; Optique non linéaire pour la commande de l'intensité, de la phase, de la polarisation ou de la couleur basés sur des éléments magnéto-optiques, p.ex. produisant un effet Faraday
41 - Éducation, divertissements, activités sportives et culturelles
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Educational and instruction services relating to arts,
crafts, sports or general knowledge; arranging, conducting
and organization of seminars; providing electronic
publications; providing online electronic publications, not
downloadable; services of reference libraries for literature
and documentary records; publication of texts, other than
publicity texts; providing non-downloadable video and audio
contents on the internet via streaming. Research, development, analysis and consultancy services in
the field of technological research; computer software
design, computer programming, or maintenance of computer
software; providing computer programs on data networks;
scientific research, development, analysis and consultancy
services in the field of quantum computing; research,
development, analysis and consultancy services in the field
of quantum communication technology; quality testing,
inspection, research, development, scientific analysis and
technological consultancy services in the fields of
pharmaceuticals, cosmetics or foodstuffs; research,
development, analysis of materials and technological
consultancy services in the fields of building construction
or city planning; environmental testing, research,
development, scientific analysis and technological
consultancy services related to the prevention of pollution;
safety testing, research, development, analysis and
technological consultancy services related to electrical
systems and power distribution; testing or research,
development, analysis and consultancy services on civil
engineering; quality testing, inspection, research,
development, scientific analysis and technological
consultancy services in the fields of agriculture, livestock
breeding or fisheries; quality testing, research,
development, scientific analysis and technological
consultancy services related to machines, apparatus and
instruments.
According to one embodiment, a liquid crystal optical element includes a first liquid crystal layer including a first cholesteric liquid crystal and a second liquid crystal layer including a second cholesteric liquid crystal, a helical pitch of each of the first cholesteric liquid crystal and the second cholesteric liquid crystal changing continuously. The first cholesteric liquid crystal including a first portion having a first helical pitch and a second portion having a second helical pitch different from the first helical pitch. The second cholesteric liquid crystal including a third portion having a third helical pitch and a fourth portion having a fourth helical pitch different from the third helical pitch.
Provided is a system for identifying facial expression of a person, the system being capable of identifying the facial expression of a person by using extension/contraction of a mask that people wear on a daily basis, and also reflect the facial expression in a motion or expression of an avatar face in a virtual space. The system comprises: a plurality of detection means 4 which are disposed in a mask 3 and include sensors that detect extension/contraction or distortion of the mask 3; a storage means 2 which stores training data that is obtained through machine learning a correspondence relationship between shape variation amounts at the respective portions of the mask 3, which are detected in the plurality of detection means 4, and a facial motion or facial expression accompanying the motion, or is obtained as a mathematical model; and an identification means 14 which compares the shape variation amounts detected in the plurality of detection means 4 and the training data and identifies the facial expression of a person.
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japon)
Inventeur(s)
Kishimoto Tadamitsu
Metwally Hozaifa Saad Hassan
Ozawa Tatsuhiko
Abrégé
The present invention provides: a sepsis and/or septic shock therapeutic agent containing, as an active ingredient, a compound that suppresses phosphorylation of threonine at position 749 of human STAT1; a method for screening a candidate compound for an active ingredient of a sepsis and/or septic shock therapeutic agent including a step for selecting a compound that suppresses phosphorylation of threonine at position 749 of human STAT1; a colitis treatment agent containing, as an active ingredient, a compound that promotes phosphorylation of threonine at position 749 of human STAT1; a method for screening a candidate compound for an active ingredient of a colitis treatment agent including a step for selecting a compound that promotes phosphorylation of threonine at position 749 of human STAT1; a systemic lupus erythematosus treatment agent containing, as an active ingredient, a compound that inhibits human STAT1; and a method for screening a candidate compound for an active ingredient of a systemic lupus erythematosus treatment agent including a step for selecting a compound that inhibits human STAT1.
A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p.ex. antiacides, antisécrétoires, protecteurs de la muqueuse
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires
The present invention realizes a reservoir calculation system capable of self-holding of an activity for a long time at a low calculation cost. The present invention comprises: an input layer (10) to which an input signal is input; a reservoir (20) which includes a plurality of modules (22) containing a plurality of units (21) to which the input signal is input; an output layer (30) which generates an output signal on the basis of output from the plurality of modules; and a learning unit (40) which adjusts a parameter used in the output layer. The plurality of units are connected to each other in each module. At least the plurality of modules are in a limit cycle or a trace mode.
Kyoto Prefectural Public University Corporation (Japon)
Inventeur(s)
Matsusaki, Michiya
Louis, Fiona
Kitano, Shiro
Sowa, Yoshihiro
Abrégé
The present invention relates to a method for freezing a cell structure including freezing a cell structure including fragmented extracellular matrix components, cells and fibrin and having a three-dimensional tissue structure.
Provided are a fuel pellet capable of being mass-produced, and a fuel pellet production method. A fuel pellet (10) comprises a fusion fuel (11) and a spherical shell membrane (12) in which the fusion fuel is accommodated, wherein the inside of the membrane (12) is filled with the fusion fuel (11) in a liquid or solid state.
This electrostimulation device MA comprises a first electrode unit 10 including a negative electrode 11 and positive electrodes 12, 12, and a second electrode unit 20 including a negative electrode 21 and positive electrodes 22, 22. A medium-frequency AC current is fed, from an electrical circuit unit CI, between the negative electrode 11 and each of the positive electrodes 12, 12, and between the negative electrode 21 and each of the positive electrodes 22, 22. The negative electrode 11 and one of the positive electrodes 12, 12, and the negative electrode 21 and one of the positive electrodes 22, 22, are disposed on skin surface positions flanking one of a pair of deep muscles to be stimulated, and the negative electrode 11 and the other positive electrode 12, and the negative electrode 21 and the other positive electrode 22, are disposed on skin surface positions flanking the other of the pair of deep muscles to be stimulated. A medium-frequency current is thereby selectively boosted in deep parts and deep muscles are stimulated in an efficient manner.
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p.ex. stimulateurs cardiaques
99.
PHARMACEUTICAL COMPOSITION AND AUTOPHAGY ACTIVATOR
The purpose of the present invention is to provide a pharmaceutical composition for treating or preventing diseases such as pulmonary diseases (excluding pulmonary fibrosis), renal diseases (excluding renal fibrosis), reproductive dysfunction, liver damage, eye diseases, skin diseases, cancer (excluding lung cancer, prostate cancer, and breast cancer), bacterial infection, viral infection, autoimmune diseases, metabolic syndrome, musculoskeletal diseases (excluding muscular dystrophy), and the like. The present invention pertains to a pharmaceutical composition that contains at least one compound selected from the group consisting of cannabidiol and compounds represented by formula (1), or a pharmaceutically acceptable salt thereof, and that is for treating or preventing at least one disease selected from the group consisting of pulmonary diseases (excluding pulmonary fibrosis), renal diseases (excluding renal fibrosis), reproductive dysfunction, liver damage, eye diseases, skin diseases, cancer (excluding lung cancer, prostate cancer, and breast cancer), bacterial infection, viral infection, autoimmune diseases, metabolic syndrome, musculoskeletal diseases (excluding muscular dystrophy), and the like.
A61K 31/495 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec deux azote comme seuls hétéro-atomes d'un cycle, p.ex. pipérazine
A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p.ex. rifampine, thiothixène
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p.ex. protecteurs hépatiques, cholagogues, cholélitholytiques
A61P 3/04 - Anorexigènes; Médicaments de l'obésité
A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins
A61P 15/00 - Médicaments pour le traitement des troubles génitaux ou sexuels; Contraceptifs
A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
A61P 19/00 - Médicaments pour le traitement des troubles du squelette
A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire
[Problem] To provide a drive control device capable of achieving high-density mount and integration of quantum bit elements used to execute an arithmetic operation by a quantum computer. [Solution] The present invention comprises a local oscillator and a quadrature mixer that applies the quadrature modulation to an output signal of the local oscillator and I/Q signals and is characterized in that the quadrature mixer is an even harmonic quadrature mixer.
